BDTX-1535 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BDTX-1535’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Small molecules are under development for the treatment of glioblastoma and non-small cell lung cancer. The drug candidates are administered orally and acts by targeting the epidermal growth factor receptor (EGFR). They are developed based on MAP (mutation, allostery and pharmacology) platform.
Black Diamond Therapeutics overview
Black Diamond Therapeutics (Black Diamond) is a precision oncology medicine company. It discovers small molecules and tumor agnostic therapies for the treatment of cancer. The company’s pipeline product candidates include BDTX-189, which targets cancers including bladder, breast, colon, endometrial, gastric and non-small cell lung cancer; and BDTX-1535, a brain-penetrant small-molecule inhibitor for the treatment of glioblastoma, affecting the brain or spine. It is also developing its Mutation-Allostery-Pharmacology (MAP) technology platform, to identify oncogenic mutations that promote cancer. Black Diamond is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of BDTX-1535’s drug-specific PTSR and LoA scores, buy the report here.